Managing hereditary ovarian cancer risk

被引:0
|
作者
Berchuck, A
Schildkraut, JM
Marks, JR
Futreal, PA
机构
[1] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
关键词
BRCA1; BRCA2; oophorectomy; ovarian cancer;
D O I
10.1002/(SICI)1097-0142(19991015)86:8+<1697::AID-CNCR8>3.0.CO;2-W
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the fourth leading cause of cancer deaths in American women. About 10% of cases are thought to have a hereditary basis, and family history is the strongest known risk factor. In the past, prophylactic oophorectomy has been advocated for women with two or more affected first-degree relatives. More recently, with the identification of the genes responsible for most hereditary ovarian cancers (BRCA1, BRCA2), oophorectomy can now be offered specifically to women who are mutation carriers. Conversely, noncarriers in these families can be reassured that their risk of ovarian cancer is not increased. The value of oophorectomy in mutation carriers has not yet been proven, however, and concern exists that the benefit may be less than intuitively expected. First, although the lifetime risk of ovarian cancer initially was reported to be as high as 60%, more recent studies have suggested risks in the range of 15 to 30%. A better understanding of the factors that underlie variable penetrance in mutation carriers is needed to augment our ability to counsel individual women. In addition, peritoneal papillary serous carcinoma indistinguishable from ovarian cancer occurs in some women after oophorectomy. Studies that better define the frequency with which this occurs are needed to establish the magnitude of the protective effect conferred by prophylactic oophorectomy. In view of the uncertainty regarding the efficacy of prophylactic oophorectomy, chemopreventive and early detection approaches also deserve consideration as strategies for decreasing ovarian cancer mortality in women who carry mutations in ovarian cancer susceptibility genes. (C) 1999 American Cancer Society.
引用
收藏
页码:1697 / 1704
页数:8
相关论文
共 50 条
  • [21] Risk Perception Among Women at Risk for Hereditary Breast and Ovarian Cancer
    Pilarski, Robert
    [J]. JOURNAL OF GENETIC COUNSELING, 2009, 18 (04) : 303 - 312
  • [22] Psychosocial Impact of Hereditary Cancer Risk Assessment on Individuals with Ovarian Cancer
    Pozzar, Rachel
    Hong, Fangxin
    Nayak, Manan
    Stopfer, Jill
    Underhill-Blazey, Meghan
    [J]. NURSING RESEARCH, 2020, 69 (03) : E150 - E151
  • [23] Gastrointestinal cancer risk in Irish hereditary breast ovarian cancer families
    Gogarty, Darragh S.
    Lyons, Tomas
    Farrell, Michael P.
    Dorman, Naoise Maria
    Green, Andrew J.
    Gallagher, David J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [24] Hereditary ovarian cancer
    Prat, J
    Ribé, A
    Gallardo, A
    [J]. HUMAN PATHOLOGY, 2005, 36 (08) : 861 - 870
  • [25] Hereditary ovarian cancer
    [J]. 1600, Israel Medical Association, Jerusalem, Israel (31): : 2 - 3
  • [26] Hereditary ovarian cancer
    Gallion, HH
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (04) : 455 - 456
  • [27] Hereditary ovarian cancer
    Langston, AA
    Ostrander, EA
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 1997, 9 (01) : 3 - 7
  • [28] Hereditary ovarian cancer
    Russo, Antonio
    Calo, Valentina
    Bruno, Loredana
    Rizzo, Sergio
    Bazan, Viviana
    Di Fede, Gaetana
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 69 (01) : 28 - 44
  • [29] Hereditary Ovarian Cancer
    Maria Alvarez-Gomez, Rosa
    Gallardo-Rincon, Dolores
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2018, 17 : 21 - 22
  • [30] Acceptable strategies for dealing with hereditary breast/ovarian cancer risk
    Eisinger, F
    Reynier, CJ
    Chabal, F
    Luquet, C
    Moatti, JP
    Sobol, H
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (10) : 731 - 731